Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Andrew J. Isbell"'
Autor:
Lauren L. Siewertsz van Reesema, Vasilena Zheleva, Janet S. Winston, Rick J. Jansen, Carolyn F. O’Connor, Andrew J. Isbell, Minglei Bian, Rui Qin, Patricia T. Bassett, Virginia J. Hinson, Kimberly A. Dorsch, Brad W. Kirby, Robert E. Van Sciver, Angela M. Tang-Tan, Elizabeth A. Harden, David Z. Chang, Cynthia A. Allen, Roger R. Perry, Richard A. Hoefer, Amy H. Tang
Publikováno v:
EBioMedicine, Vol 11, Iss C, Pp 183-198 (2016)
Background: Metastatic breast cancer exhibits diverse and rapidly evolving intra- and inter-tumor heterogeneity. Patients with similar clinical presentations often display distinct tumor responses to standard of care (SOC) therapies. Genome landscape
Externí odkaz:
https://doaj.org/article/65a73692ab8c408685ec6d1a14fec41e
Autor:
Brad W. Kirby, Andrew J. Isbell, David Z. Chang, Virginia J. Hinson, Richard A. Hoefer, Robert E. Van Sciver, Carolyn F. O’Connor, Rick J. Jansen, Minglei Bian, Cynthia A. Allen, Vasilena Zheleva, Rui Qin, Patricia T. Bassett, Janet S. Winston, Angela M. Tang-Tan, Roger R. Perry, Amy H. Tang, Lauren L. Siewertsz van Reesema, Elizabeth A. Harden, Kimberly A. Dorsch
Publikováno v:
EBioMedicine, Vol 11, Iss C, Pp 183-198 (2016)
EBioMedicine
EBioMedicine
Background Metastatic breast cancer exhibits diverse and rapidly evolving intra- and inter-tumor heterogeneity. Patients with similar clinical presentations often display distinct tumor responses to standard of care (SOC) therapies. Genome landscape
Autor:
Andrew J. Isbell, R. E. Van Sciver, Elizaveta Svyatova, J.K. Bruflat, Justin J. Odanga, Rebecca L. Schmidt, J.L. Eisner, Minglei Bian, Amy H. Tang, Vasilena Zheleva, L.L. Siewertsz van Reesema, Monicah M. Njogu, Angela M. Tang-Tan
Oncogenic K-RAS mutations are found in ∼30% of all human cancers, and K-RAS “pathway” activation is prevalent in high-grade cancer, making active K-RAS an ideal target for drug development. Despite intense research efforts in the past 30 years,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4b0f8fe7ad260d20531a409b2e0b53b
https://doi.org/10.1016/b978-0-12-803505-4.00012-6
https://doi.org/10.1016/b978-0-12-803505-4.00012-6
Autor:
Yang Liao, Justin J. Odanga, Zena M. Urban, Richard A. Hoefer, Minglei Bian, Monicah M. Njogu, Vasilena Zheleva, Andrew J. Isbell, Gloria M. Petersen, Roger R. Perry, Amy H. Tang, Thomas C. Smyrk
Publikováno v:
Molecular Cancer Research. 12:A26-A26
Oncogenic K-RAS activation is a major menace that drives aggressive tumor progression and metastasis in 30% of all human cancer. Currently, there are no effective therapies to treat stage III and IV metastatic human cancers with oncogenic K-RAS hyper
Autor:
Andrew J. Isbell, Gloria M. Petersen, Roger R. Perry, Xiaofei Gao, Amy H. Tang, Monicah M. Njogu, Rie Takahashi, Justin J. Odanga, Richard A. Hoefer, Vasilena Zheleva, Minglei Bian, Rebecca L. Schmidt, Thomas C. Smyrk, Zena M. Urban, Yang Liao
Publikováno v:
Cancer Research. 73:C62-C62
Hyperactive ERBB/K-RAS signaling is a major menace that drives aggressive tumor growth and metastasis in human cancer. Currently, there are no effective ways to treat late-stage and relapsed human cancers that have oncogenic ERBB/K-RAS mutations that